Hims & Hers Health Announces Strategic Shift in U.S. Weight Loss Business

Details

announced a strategic shift in its U.S. weight loss business, entering into a collaboration with Novo Nordisk to align its domestic and global strategies around FDA-approved GLP-1s. The company plans to cease advertising compounded GLP-1 offerings and will focus on offering a broad range of FDA-approved medications. Existing patients will be transitioned to FDA-approved medicines where clinically appropriate, and compounded GLP-1s will be offered on a limited basis. The collaboration includes the introduction of Ozempic and Wegovy to the platform. Concurrently, Novo Nordisk dismissed its lawsuit against Hims & Hers without prejudice.

Items reported

About Hims & Hers Health, Inc.

Hims & Hers Health, Inc. is a telehealth service provider that aims to simplify and enhance healthcare access for consumers. The company specializes in personal care and wellness products and services, offering both prescription and over-the-counter solutions. With a focus on destigmatizing health and wellness issues, Hims & Hers addresses areas such as dermatology, sexual health, hair care, and mental wellness, appealing to a broad demographic looking for convenient and private healthcare options. By facilitating online consultations with licensed medical professionals, the company allows users to receive medical advice, treatments, and prescriptions, all accessible from the comfort of their homes. Hims & Hers plays a significant role in the growing digital healthcare market, leveraging technology to provide more accessible and personalized healthcare experiences. Headquartered in San Francisco, the company capitalizes on the increase in demand for telehealth services, buoyed by advancements in digital health trends and the expanding e-commerce space for healthcare solutions.